Lipoprotein lipase (LPL), hydrolyzes the core triglycerides of lipoproteins, thereby playing a role in their maturation. LPL may be important in the metabolic pathways that lead to atherosclerosis, since it is secreted in vitro by both of the predominant cell types of the atherosclerotic plaque, i.e., macrophages and smooth muscle cells. Because of uncertainty concerning the primary cellular source of LPL in atherosclerotic lesions, in situ hybridization assays for LPL mRNA were performed on 12 coronary arteries obtained from six cardiac allograft recipients. Macrophages Invest. 1992Invest. . 89:1544Invest. -1550 
Introduction
Lipoprotein lipase (LPL)1 is an enzyme that hydrolyzes the core triglycerides of chylomicrons and very low density lipoproteins, thereby playing a role in their metabolism. It also hydrolyzes triglycerides in the core of low density lipoprotein, thereby remodeling this lipoprotein class as well (1) . Zilversmit (2) first proposed that LPL may be important in atherosclerosis by hypothesizing that hydrolysis of the triglyceride-rich lipoproteins by LPL at the endothelial lining of arteries could lead to the formation of atherogenic remnants, which might be taken up by arterial wall cells and lead to cholesterol deposition. He subsequently demonstrated the presence ofLPL activity in the intima of bovine aorta (3) .
LPL was shown to be produced by murine peritoneal (4), human monocyte-derived (5, 6) , and rabbit alveolar (6) macrophages, and by pig aortic smooth muscle cells (7) . However, LPL production by cultured human arterial smooth muscle cells has never been reported. In vitro experiments have also demonstrated that LPL might promote lipid accumulation by cells (8, 9) . LPL can metabolize VLDL and chylomicrons to remnants which have an increased rate of uptake by macrophages (8) . LPL also can modify LDL to a form with an increased rate of uptake by both macrophages and smooth muscle cells (9) . Thus, in vitro studies have demonstrated that LPL may be produced by both of the predominant cell types of the plaque, i.e., macrophages and smooth muscle cells, and may modify certain lipoproteins to forms that are taken up more readily by cells.
In addition to the observations of Zilversmit 
Methods
Arterial tissue. 12 coronary artery segments were obtained from hearts removed from six patients undergoing orthotopic cardiac transplanta-tion. These segments were fixed in either fresh 4% paraformaldehyde or 10% formalin and paraffin-embedded. The etiology ofcardiomyopathy was idiopathic in three patients, ischemic in two, and valvular in one.
Immunocytochemistry. Single-label immunoperoxidase staining of tissues was performed as described previously (12) , using the cell-specific monoclonal antibodies HAM-56, which recognizes human macrophages (13), and HHF-35, which recognizes muscle cell actin, and therefore is specific for smooth muscle cells when used in this context (12) . HHF-35 and HAM-56 were kindly provided by Dr. Allen Gown, University of Washington. HAM-56 was used at a titer of 1:4,000 and HHF-35 at a titer of 1:10,000. Briefly, tissue sections were deparaffinized with xylene, rehydrated with graded alcohols, and washed with phosphate-buffered saline. The slides were incubated (30 min) with the primary antibody, washed with PBS, after which a biotin-labeled secondary antibody was applied (30 min), followed by an avidin-biotinylated-peroxidase conjugate (30 min 250 MCi "S-UTP (1,100-1,300 Ci/mmol), 500 MuM each of ATP, CTP, and GTP, 40 U RNasin, 10 mM dithiothreitol, 40 mM Tris, and 10 U of either T7 or SP6 polymerase. After 60-75 min at 37°C, the cDNA was digested by adding 1 U DNase (Promega) and incubation at 37°C for an additional 15 min. Free nucleotides were then separated using a Sephadex G-50 column. Specific activity of the probes ranged from 5 to 30 x 107 cpm/mg. Probes were stored at -70°C and used within 24 h of synthesis.
In situ hybridization. Arterial tissue which had been fixed in 4% paraformaldehyde or 10% formalin and embedded in paraffin was deparaffinized following standard protocol. The sections were washed with 0.5x standard saline citrate (SSC) (lX SSC = 150 mM NaCl, 15 mM Na citrate, pH 7.0), digested with proteinase K (1 gg/mL) (Sigma) in RNase A (Promega) buffer, and then postfixed for 10 min in paraformaldehyde. Several 0.5x SSC washes were followed by prehybridization for 2 h in 50 Ml of prehybridization buffer (0.3 M NaCl, 20 mM Tris pH 8.0, 5 mM EDTA, IX Denhardt's solution, 10% dextran sulfate, 10 mM DTT). The hybridizations were started by adding 500,000 cpm of "S-labeled riboprobe in 50 Al of prehybridization buffer and allowed to proceed overnight at 50°C. After hybridization, sections were washed with 0.5x SSC, treated with RNase A (20 jig/ml, 30 min room temperature), washed in 2x SSC (2 X 2 min), followed by three high stringency washes in 0.1X SSC/Tween 20 (Sigma) at 37°C, followed by several 2x SSC washes. After the tissue was air dried, it was dipped in NTB2 nuclear emulsion (Kodak) and exposed in the dark at 4°C for 4 wk. After developing, the sections were counterstained with either hematoxylin and eosin or methyl green, dehydrated, and mounted. (Promega) was added to the primary and secondary antibodies and to the avidinbiotin complex at a concentration of 180 U/ml; (b) antibodies were used at two-to fourfold higher concentrations due to the RNasin treatment; and (c) PBS was treated with diethyl pyrocarbonate (Sigma). In situ hybridization then followed immediately and by standard protocol.
Results
Immunocytochemistry and in situ hybridization ofadjacent arterial sections. A low power photomicrograph ofa hematoxylin and eosin-stained section from one of the arteries included in the study is shown in Fig. 1 a. Higher power photomicrographs of the foam cell-rich region in the lower right-hand portion of the artery from adjacent sections of the same artery stained with the cell-specific antibodies show that black grains representing hybridized antisense LPL riboprobe (Fig. 1 b) In contrast, macrophages, as identified by the antibody HAM-56, are located primarily in the center of this portion of the plaque intima (Fig. 1 c) . Using a sense LPL riboprobe, no specific hybridization is detected (data not shown).
Immunocytochemistry with anti-LPL antibody LPL-5780. LPL protein, as detected immunocytochemically by antibody LPL-5780 staining, was present in association with macrophage-derived foam cells, endothelial cells, adventitial adipocytes, and arterial media underlying sections of intima which were uninvolved with plaque, or which had only diffuse intimal thickening (Fig. 2 a) . The staining was particularly strong in foam cell-rich regions (Fig. 2 b) . Specific staining with the antibody was also present, though markedly diminished, in intimal smooth muscle cells and in arterial media underlying areas of well-developed plaque (Fig. 2 c) .
Distribution of LPL mRNA and cell types in 12 coronary arterial segments. The intima of 48 quadrants from 12 coronary arterial segments were examined for the presence or absence of foam cells, macrophages, smooth muscle cells, and LPL mRNA. Of the 48 quadrants, foam cells were present in 10 (21%), macrophages were identified in 29 (60%), smooth muscle cells were present in 46 (96%), and LPL mRNA was detected by in situ hybridization in 11 Combined immunocytochemistry and in situ hybridization. Fig. 3 shows a high power photomicrograph of a lesion stained with the macrophage-specific marker, HAM-56, and hybridized with the LPL riboprobe. The black silver grains, which indicate the presence of LPL mRNA, are associated with cells that can be identified as foam cells as evidenced by their morphology, and as ofmacrophage origin by their staining with the macrophage-specific antibody. Fig. 4 shows a high power photomicrograph of the fibrous cap of an adjacent section of the same lesion as shown in Fig. 3 , but which has now been stained with the smooth muscle cell-specific antibody, HHF-35, and hybridized with the LPL riboprobe. Smooth muscle cells (brown reaction product) are not associated with the black silver grains that represent LPL mRNA. These findings contrast with the results of Jonasson et al. (1 1) , who found that LPL protein, as identified by a polyclonal antibody, was found primarily in association with smooth muscle cells that did not express the major histocompatibility complex antigen HLA-DR, but only with a small minority of macrophages, and not with any foam cells.
Discussion
The findings of the present study strongly suggest that macrophages and, in particular, macrophage-derived foam cells rather than smooth muscle cells, are the primary cellular source of LPL, as detected by in situ hybridization, in human coronary plaques. In vitro and in vivo experiments have diverged in their conclusions about which of the cells of the plaque produce LPL. For example, several groups have been able to demonstrate the production of large quantities of LPL by cultured murine peritoneal (4) , human blood monocytederived (5, 6), and rabbit alveolar (6) macrophages. Only one group has been able to demonstrate the production ofrelatively small quantities of LPL by pig aortic smooth muscle cells (7) . In contrast, available data from a limited number of in vivo experiments have suggested that LPL protein is mostly associated with vascular smooth muscle cells, rather than macrophages. Camps et al. (10) have demonstrated that both LPL mRNA, as detected by in situ hybridization, and LPL protein as detected immunocytochemically, are associated with normal medial smooth muscle cells in guinea pig aorta. Neither atherosclerotic guinea pig aortas nor macrophages were examined in that study. Jonasson et al. (1 1) have detected LPL protein in association with HLA-DR-negative smooth muscle cells, but not to any significant degree with HLA-DR-positive smooth muscle cells, macrophages, or foam cells in human carotid plaques. Thus LPL has been most readily identified with macrophages in cell culture, but with smooth muscle cells in arterial tissue.
While the present study confirms that LPL protein is associated with some intimal smooth muscle cells, it is present at a much lower level than that found in macrophage-derived foam cells. Further, LPL staining of media underlying areas of welldeveloped plaque is less than that found in media underlying either normal intima or intima with diffuse thickening. One explanation for the difference between the findings of the present study and that of Jonasson et al. is that there may be a difference between the cellular source of LPL mRNA in human carotid plaques used in their study and human coronary arteries used in the present study. This explanation seems unlikely, however, as it would imply the presence of fundamentally different stimuli for, or mediators of, atherogenesis in the human carotid and coronary circulations. Another possibility is that the LPL associated with intimal smooth muscle cells in both the study of Jonasson et al. and in the present study, was synthesized and secreted by macrophages. It is well recognized that LPL may associate with cells other than those in which it was produced, the best example being endothelial cells (10). The findings in the present study are consistent with the observation that macrophages in culture produces large amounts of LPL (4, 5, 6) . A third possibility is that smooth muscle cells accumulate LPL mRNA in amounts that are beyond the level of detection by the in situ hybridization method used. Alternatively, but much less likely given the lability ofthe LPL protein, LPL LPL mRNA expressed by cells at a relatively low level. This could also explain our inability to detect LPL mRNA in medial smooth muscle cells. Because a certain amount of nonspecific background is invariably present when radioactively labelled riboprobes are used, low level mRNA expression may not provide sufficient signal above background to allow detection. Examination ofsections stained with the antisense riboprobe used in our study show that very little background is present. Therefore, if LPL mRNA expression was present but not detected in some macrophages or in smooth muscle cells, the levels of mRNA present would be much lower than that seen in foam cells. However, this would not invalidate the conclusion that macrophage-derived foam cells are the primary cellular source of LPL in human coronary plaques, consistent with observations in vitro. Low level expression or lack ofexpression ofLPL by some intimal macrophages suggests that these macrophages may be under the influence of cytokines which inhibit LPL expression, such as interferon-gamma (17, 18) produced by T lymphocytes. In addition, Hansson et al., have shown that T lymphocytes are present in human atherosclerotic lesions (19) and in lesions from cholesterol-fed rabbits (20), suggesting that T lymphocyte-derived cytokines such as interferon-gamma may be involved in atherogenesis. If intimal T lymphocytes have the ability to retard atherogenesis, one way in which they might do this is by suppressing LPL expression by neighboring macrophages through secretion of interferon-gamma.
Whether LPL might play a role in the pathogenesis of atherosclerosis is unknown, but Zilversmit has postulated that LPL may promote atherosclerosis, by modifying triglyceriderich lipoproteins at the endothelial surface to atherogenic remnants (2) . In vitro experiments which demonstrate that LPL may modify VLDL (8) and LDL (9) to more atherogenic forms support the hypothesis that LPL expressed in atherosclerotic plaques may be proatherogenic. The present study demonstrates that LPL is expressed in the intima of plaques, being produced primarily by the most lipid-laden cells of the plaque, i.e., macrophage-derived foam cells. Further, LPL mRNA may be expressed by some intimal non-foam cell macrophages, raising the possibility that LPL plays a role in the lipid accumulation that is a hallmark of their morphologic transformation into foam cells, although its presence in macrophages does not necessarily imply a role for LPL in this process. Some subjects who are heterozygous for LPL deficiency might be at increased risk of atherosclerosis by virtue ofthe atherogenic profiles seen in this situation (21) . However, sufficient LPL is likely to be present in the milieux of the artery wall for local modification of lipoproteins by macrophage-derived LPL.2
